Reuters logo
BRIEF-Thrombogenics regains global rights to Jetrea
September 18, 2017 / 8:26 AM / a month ago

BRIEF-Thrombogenics regains global rights to Jetrea

Sept 18 (Reuters) - THROMBOGENICS NV:

* THROMBOGENICS NV : THROMBOGENICS REGAINS GLOBAL RIGHTS TO JETREA (OCRIPLASMIN)

* ‍ALCON AND NOVARTIS WILL WORK CLOSELY WITH THROMBOGENICS TO ENSURE CONTINUITY AND ACCESS TO JETREA FOR CUSTOMERS.

* UNDER THE TERMS OF THE AGREEMENT, THROMBOGENICS RECEIVES A CASH AMOUNT OF €53.7 MILLION AND A FORTHCOMING EQUITY INVESTMENT OF €10 MILLION IN THROMBOGENICS CAPITAL. ​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below